Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer

被引：9

作者：

Piotrowska, Zofia ^{[1
,2
]}

Drapkin, Benjamin ^{[1
]}

Engelman, Jeffrey A. ^{[1
,2
]}

Nagy, Rebecca J. ^{[3
]}

Lanman, Richard B. ^{[3
]}

Sequist, Lecia V. ^{[1
,2
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA

[2] Harvard Med Sch, Boston, MA USA

[3] Guardant Hlth Inc, Redwood City, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 08期

关键词：

D O I：

10.1016/j.jtho.2016.03.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：E95 / E97

页数：5

共 50 条

[21] Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M?
Park, S.
Ahn, M-J.
ANNALS OF ONCOLOGY, 2020, 31 (11) : 1582 - 1582
[22] Predictive factors and prognostic significance of T790M mutation in patients with EGFR-mutant NSCLC
Hwang, Ji An
Choi, Chang-Min
Lee, Jae Cheol
EUROPEAN RESPIRATORY JOURNAL, 2017, 50
[23] Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC)
Kris, Mark G.
Oxnard, Geoffrey R.
Johnson, Bruce E.
Berry, Lynne D.
Chen, Heidi
Kwiatkowski, David J.
Iafrate, Anthony John
Wistuba, Ignacio Ivan
Franklin, Wilbur A.
Aisner, Dara
Sequist, Lecia V.
Khuri, Fadlo Raja
Garon, Edward B.
Pao, William
Rudin, Charles M.
Schiller, Joan H.
Haura, Eric B.
Minna, John D.
Bunn, Paul A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[24] EGFR-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing
Sukari, Ammar
Nagasaka, Misako
Wakeling, Erin
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (10): : 1188 - 1192
[25] Molecular Docking Analysis on the Designed Benzimidazole Derivatives as EGFR Inhibitors: Comparison between EGFR Wild-Type (EGFRWT) and T790M Mutant
Jalil, Nurul Awani Syazzira
Abd Hamid, Shafida
SAINS MALAYSIANA, 2023, 52 (04): : 1203 - 1215
[26] Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
Janjigian, Yelena Y.
Smit, Egbert F.
Groen, Harry J. M.
Horn, Leora
Gettinger, Scott
Camidge, D. Ross
Riely, Gregory J.
Wang, Bushi
Fu, Yali
Chand, Vikram K.
Miller, Vincent A.
Pao, William
CANCER DISCOVERY, 2014, 4 (09) : 1036 - 1045
[27] The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
Tseng, Jeng-Sen
Su, Kang-Yi
Yang, Tsung-Ying
Chen, Kun-Chieh
Hsu, Kuo-Hsuan
Chen, Hsuan-Yu
Tsai, Chi-Ren
Yu, Sung-Liang
Chang, Gee-Chen
ONCOTARGET, 2016, 7 (30) : 48059 - 48069
[28] Genomic Analysis of Tumor and Plasma in T790M Mutant Positive EGFR Lung Cancer Patients before and after Osimertinib Treatment
Yang, J. C.
Yu, C.
Shih, J.
Ho, C.
Liao, W.
Lee, J.
Tsai, T.
Su, K.
Shih, M.
Chang, Y. L.
Bai, Y.
Huang, D.
Thress, K.
Lin, C.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2230 - S2231
[29] Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer
Kawamura, Takahisa
Kenmotsu, Hirotsugu
Omori, Shota
Nakashima, Kazuhisa
Wakuda, Kazushige
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Omae, Katsuhiro
Mori, Keita
Tanigawara, Yusuke
Nakajima, Takashi
Ohde, Yasuhisa
Endo, Masahiro
Takahashi, Toshiaki
CLINICAL LUNG CANCER, 2018, 19 (02) : E247 - E252
[30] The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
Zhang, Qiuyi
Ke, Ee
Niu, Feiyu
Deng, Wei
Chen, Zhihong
Xu, Chongrui
Zhang, Xuchao
Zhao, Ning
Su, Jian
Yang, Jinji
Yan, Honghong
Wu, Yilong
Zhou, Qing
ONCOTARGET, 2017, 8 (03) : 4994 - 5002

← 1 2 3 4 5 →